Alpha Teknova

Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teknova reports mixed Q4 results, focuses on cost optimization

Teknova's Q4 2022 earnings call highlighted a mixed financial performance with revenue decline offset by full-year growth, emphasizing the importance of strategic investments and operational efficiency.
Challenges in profitability, including a net loss and negative adjusted EBITDA, underscore the need for cost management and revenue optimization strategies to drive sustainable growth.
Despite facing financial hurdles, Teknova's focus on balancing cost reduction with growth initiatives and maintaining liquidity sets the stage for future financial resilience and market competitiveness.

Teknova reports mixed Q1 2023 results, eyes growth opportunities

Teknova's Q1 2023 performance showed a mix of positive and negative indicators, with revenue growth and expense management as strengths, while challenges include declining total revenue and negative adjusted EBITDA. The company's focus on innovation, cost control, and market research presents opportunities for future growth and margin improvement.

TEKNOVA reports robust Q2 revenue growth amidst operational optimizations

TEKNOVA's Q2 2023 showed strong revenue growth and operational improvements.
Despite challenges, the company remains optimistic about its future growth prospects.
Strategic investments in R&D and manufacturing capabilities position TEKNOVA for long-term success.
Efforts to manage expenses and achieve free cash flow targets are key priorities.

Alpha Teknova reports Q3 revenue decline, focuses on financial stability

Alpha Teknova (TKNO) faced revenue declines in Q3 2023, with a net loss of $10.2 million and negative adjusted EBITDA of $5.5 million.
Despite challenges, the company strengthened its financial position through a direct offering, debt repayment, and cost reduction initiatives.
Teknova's focus on managing costs, cash outflows, and strategic investments underscores its commitment to financial stability and operational efficiency.
While facing performance headwinds, Teknova aims to navigate challenges and leverage opportunities for sustainable growth and improved profitability.

Teknova maintains stability, eyes growth through cost savings and partnerships

Teknova's Q4 2023 performance showed stability in revenue and operational improvements, with a focus on cost-saving initiatives and revenue guidance for 2024.
Despite challenges in Clinical Solutions and margin pressures, Teknova's strong customer service, cost reductions, and market opportunities position it for growth.
Strategic partnerships, industry-leading Net Promoter Scores, and a positive outlook on cell and gene therapy approvals present avenues for revenue enhancement and market expansion.

Alpha Teknova (TKNO) reports solid Q1 performance amidst profitability challenges

Alpha Teknova (TKNO) delivered a strong performance in Q1 2024, showcasing revenue growth, cost management success, and operational highlights.
While facing challenges with negative adjusted EBITDA and maintaining gross margin, Teknova's strengths lie in expense management, innovation, and market positioning.
Opportunities for Teknova include product launches, market stabilization, and customer base expansion, setting the stage for future growth and success.
To sustain growth, Teknova must address profitability challenges, balance expense management with revenue growth, and capitalize on market opportunities.

Alpha Teknova (TKNO) reports Q2 growth, eyes profitability without funding

Alpha Teknova (TKNO) showed improved sequential revenue and EBITDA performance in Q2 2024. The company introduced new high-margin offerings and closed a capital raise to drive profitability. Challenges include YoY revenue decline and the need for market stabilization.

Alpha Teknova (TKNO) reports robust Q3 results and outlines growth strategies

Alpha Teknova's Q3 2024 earnings call highlighted strong financial performance, growth in key segments, and ongoing efforts to enhance profitability. While facing challenges in certain revenue streams, the company remains optimistic about its outlook and strategic initiatives for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2024 Earnings Conference Call November 7, 2024 5:30 PM ET Company Participants Jennifer Henry – Senior Vice President-Marketing Stephen Gunstream – President and Chief Executive Officer Matt Lowell – Chief Financial Officer Conference Call Participants Chad Wiatrowski – TD Cowen Lucas Baranowski – KeyBanc Capital Markets Vidyun Bais – BTIG Jacob Johnson – Stephens Matt Larew – William Blair Operator Hello, and welcome to Alpha Teknova Third Quarter 2024 Financial Results. At this time all participants are in a listen-only mode.

Alpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call Transcript

Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior year Company lowers 2024 total free cash outflow outlook to less than $16 million Company reaffirms 2024 revenue guidance of $35-38 million

Teknova Reports Third Quarter 2024 Financial Results

HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market.

Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024

Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Alpha Teknova (TKNO) a Strong Momentum Stock: Buy Now?

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Jennifer Henry - SVP, Marketing Stephen Gunstream - President & CEO Matt Lowell - CFO Conference Call Participants Mark Massaro - BTIG Jacob Johnson - Stephens Steven Mah - TD Cowen Paul Knight - KeyBanc Matt Larew - William Blair Operator Good day and thank you for standing by. Welcome to the Teknova's Second Quarter 2024 Financial Results.

Alpha Teknova, Inc. (TKNO) Q2 2024 Earnings Call Transcript

Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million

Teknova Reports Second Quarter 2024 Financial Results

HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market.

Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024

Appian

Barnes & Noble Education

Citi Trends

Noble Corp PLC

24/7 Insights With the new quarter begun and second-quarter earnings reports starting to come in, insider buying has slowed to a trickle.

Recent Insider Buying Is Focused on These 5 Stocks

HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.

Teknova Announces Closing of $15.4 Million Private Placement

HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.

Teknova Announces $15.4 Million Private Placement

Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today provided a business update including preliminary unaudited financial results for the second quarter ended June 30, 2024.

Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results

Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -24.59% in 4 Weeks, Here's Why the Trend Might Reverse for Alpha Teknova (TKNO)

Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Alpha Teknova (TKNO) Upgraded to Buy: What Does It Mean for the Stock?

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President and Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Steven Mah - TD Cowen Matt Larew - William Blair Vidyun Bais - BTIG Operator Good day and thank you for standing by. Welcome to Teknova's First Quarter 2024 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) Q1 2024 Earnings Call Transcript

First quarter 2024 total revenue was $9.3 million, up 2% from prior year Launch of Build-Tek™  Custom Configurator Company reaffirms 2024 revenue guidance of $35-38 million

Teknova Reports First Quarter 2024 Financial Results

First-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times

Teknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy Development

HOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, following the close of market.

Teknova to Report First Quarter 2024 Financial Results on May 13, 2024

The heavy selling pressure might have exhausted for Alpha Teknova (TKNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -28.04% in 4 Weeks, Here's Why Alpha Teknova (TKNO) Looks Ripe for a Turnaround

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2023 Earnings Conference Call March 11, 2024 5:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Jacob Johnson - Stephens Steven Mah - TD Cohen Madeline Mollman - William Blair Paul Knight - KeyBanc Operator Hello, and thank you for standing by. Welcome to Teknova Fourth Quarter 2023 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) Q4 2023 Earnings Call Transcript

Full year 2023 total revenue was $36.7 million, down 11% year-over-year Achieved 36% annual growth in the number of Clinical Solutions customers in 2023 Company provides 2024 revenue guidance of $35-38 million

Teknova Reports Fourth Quarter and Full Year 2023 Financial Results

HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024, following the close of market.

Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Alpha Teknova, Inc. (TKNO) Q3 2023 Earnings Call Transcript

Raised $22.9 million of equity capital, paid down $10.0 million of long-term debt Third quarter 2023 total revenue was $8.2 million, down 24% from prior year Expect 2023 revenue at the low end of previously announced guidance range of $37-40 million HOLLISTER, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2023.

Teknova Reports Third Quarter 2023 Financial Results

Teknova today announced that the Company will report its financial results for the third quarter on Thursday, November 9, 2023, following close of market.

Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023

Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV constructs and workflows Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV constructs and workflows

News for Alpha Teknova Stock (TKNO)